Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 ataluren study in nonsense mutation aniridia
2022-001013-39Phase 2
- Sponsor
- PTC Therapeutics, Inc
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in aniridia comparing Ataluren with Placebo (2 arms). Primary endpoint: Change from baseline in maximum reading speed of both eyes at Week 48.
02
Drugs
ataluren
03
Conditions
aniridia
Beyond the preview
Go deeper on 2022-001013-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001013-39.